Receptor News and Research

RSS

Researchers discover new marker derived from human umbilical cord blood

The development of stem cell therapies to cure a variety of diseases depends on the ability to characterize stem cell populations based on cell surface markers.

18 Apr 2014

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

A Northwestern University synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.

18 Apr 2014

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial.

From Medtronic 18 Apr 2014

Researchers uncover mechanism that may help explain severe forms of schistosomiasis

Researchers at the Sackler School of Graduate Biomedical Sciences at Tufts and Tufts University School of Medicine (TUSM) have uncovered a mechanism that may help explain the severe forms of schistosomiasis, or snail fever, which is caused by schistosome worms and is one of the most prevalent parasitic diseases in the world. The study in mice, published online in The Journal of Immunology, may also offer targets for intervention and amelioration of the disease.

17 Apr 2014

Findings offer new paths towards improved fertility treatments and development of new contraceptives

Researchers at the Wellcome Trust Sanger Institute have discovered interacting proteins on the surface of the sperm and the egg essential to begin mammalian life. These proteins, which allow the sperm and egg to recognize one another, offer new paths towards improved fertility treatments and the development of new contraceptives.

17 Apr 2014

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure.

17 Apr 2014

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy.

17 Apr 2014

Freiburg researchers discover molecule that smuggles toxins from intestinal pathogens into human cells

Prof. Dr. Dr. Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Freiburg have discovered the receptor responsible for smuggling the toxin of the bacterium Clostridium perfringens into the cell.

17 Apr 2014

Understanding GPCRs and controlling inflammation: an interview with Dr. Richard Proia, NIDDK, NIH

GPCRs are one of the largest families of cellular signalling proteins consisting of more than a thousand different types. They reside on the surface membranes of cells where they are poised to recognize molecules in the exterior environment and then transmit this information through the membrane allowing cells to respond accordingly.

16 Apr 2014

UC pain researcher solves a long-standing scientific mystery

By solving a long standing scientific mystery, the common saying "you just hit a nerve" might need to be updated to "you just hit a Merkel cell," jokes Jianguo Gu, PhD, a pain researcher at the University of Cincinnati.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

Study shows how infection worsens damage caused by stroke

Infection is bad news for all of us - but it can be really serious to people who have had a stroke. Evidence is mounting that infection makes things much worse after a stroke.

15 Apr 2014

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.

15 Apr 2014

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Northwestern Medicine scientists are continuing to unravel the molecular changes that underlie one of the world's deadliest and most infamous respiratory infections.

15 Apr 2014

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

11 Apr 2014

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Cardiovascular Institute are among the 2014 recipients of the prestigious Clinical Research Achievement Award for their work in cardiovascular science.

11 Apr 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

Receptor News and Research

Researchers discover new marker derived from human umbilical cord blood

Engineering cell-based, biological devices may selectively kill cancer cells without disrupting healthy cells

ARCA biopharma announces genetic screening of first patient in GENETIC-AF Phase 2B/3 clinical trial

Researchers uncover mechanism that may help explain severe forms of schistosomiasis

Findings offer new paths towards improved fertility treatments and development of new contraceptives

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Freiburg researchers discover molecule that smuggles toxins from intestinal pathogens into human cells

Understanding GPCRs and controlling inflammation: an interview with Dr. Richard Proia, NIDDK, NIH

UC pain researcher solves a long-standing scientific mystery

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Protein expression predicts postop NSCLC recurrence, survival

Study shows how infection worsens damage caused by stroke

Obeticholic acid meets primary composite endpoint in Phase III study

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Adoptive T-cell therapy may help in treating liver cancer, says study

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News